Department of Molecular Biomedical Sciences, North Carolina State University, Raleigh, North Carolina 27606, USA.
Invest Ophthalmol Vis Sci. 2010 Sep;51(9):4437-46. doi: 10.1167/iovs.09-3861.
PURPOSE: The iron storage protein ferritin is necessary for the safe storage of iron and for protection against the production of iron-catalyzed oxidative damage. Ferritin is composed of 24 subunits of two types: heavy (H) and light (L). The ratio of these subunits is tissue specific, and alteration of this ratio can have profound effects on iron storage and availability. In the present study, siRNA for each of the chains was used to alter the ferritin H:L chain ratio and to determine the effect of these changes on ferritin synthesis, iron metabolism, and downstream effects on iron-responsive pathways in canine lens epithelial cells. METHODS: Primary cultures of canine lens epithelial cells were used. The cells were transfected with custom-made siRNA for canine ferritin H- and L-chains. De novo ferritin synthesis was determined by labeling newly synthesized ferritin chains with 35S-methionine, immunoprecipitation, and separation by SDS-PAGE. Iron uptake into cells and incorporation into ferritin was measured by incubating the cells with 59Fe-labeled transferrin. Western blot analysis was used to determine the presence of transferrin receptor, and ELISA was used to determine total ferritin concentration. Ferritin localization in the cells was determined by immunofluorescence labeling. VEGF, glutathione secretion levels, and cystine uptake were measured. RESULTS: FHsiRNA decreased ferritin H-chain synthesis, but doubled ferritin L-chain synthesis. FLsiRNA decreased both ferritin H- and L-chain synthesis. The degradation of ferritin H-chain was blocked by both siRNAs, whereas only FHsiRNA blocked the degradation of ferritin L-chain, which caused significant accumulation of ferritin L-chain in the cells. This excess ferritin L-chain was found in inclusion bodies, some of which were co-localized with lysosomes. Iron storage in ferritin was greatly reduced by FHsiRNA, resulting in increased iron availability, as noted by a decrease in transferrin receptor levels and iron uptake from transferrin. Increased iron availability also increased cystine uptake and glutathione concentration and decreased nuclear translocation of hypoxia-inducible factor 1-alpha and vascular endothelial growth factor (VEGF) accumulation in the cell-conditioned medium. CONCLUSIONS: Most of the effects of altering the ferritin H:L ratio with the specific siRNAs were due to changes in the availability of iron in a labile pool. They caused significant changes in iron uptake and storage, the rate of ferritin synthesis and degradation, the secretion of VEGF, and the levels of glutathione in cultured lens epithelial cells. These profound effects clearly demonstrate that maintenance of a specific H:L ratio is part of a basic cellular homeostatic mechanism.
目的:铁储存蛋白铁蛋白对于安全储存铁和防止铁催化的氧化损伤的产生是必需的。铁蛋白由两种类型的 24 个亚基组成:重(H)链和轻(L)链。这些亚基的比例是组织特异性的,并且这种比例的改变会对铁的储存和可用性产生深远的影响。在本研究中,使用每种链的 siRNA 来改变铁蛋白 H:L 链比,并确定这些变化对犬晶状体上皮细胞中铁蛋白合成、铁代谢以及对铁反应途径的下游影响。
方法:使用犬晶状体上皮细胞的原代培养物。用定制的犬铁蛋白 H-和 L-链 siRNA 转染细胞。通过用 35S-甲硫氨酸标记新合成的铁蛋白链、免疫沉淀和 SDS-PAGE 分离来确定新合成的铁蛋白的合成。通过孵育细胞 59Fe-标记转铁蛋白来测量细胞内铁的摄取和掺入铁蛋白。使用 Western blot 分析来确定转铁蛋白受体的存在,使用 ELISA 来确定总铁蛋白浓度。通过免疫荧光标记来确定铁蛋白在细胞中的定位。测量 VEGF、谷胱甘肽分泌水平和胱氨酸摄取。
结果:FHsiRNA 降低了铁蛋白 H 链的合成,但使铁蛋白 L 链的合成增加了一倍。FLsiRNA 降低了铁蛋白 H-和 L-链的合成。两种 siRNA 均阻断了铁蛋白 H 链的降解,而只有 FHsiRNA 阻断了铁蛋白 L 链的降解,导致细胞内铁蛋白 L 链的大量积累。这种过量的铁蛋白 L 链存在于包含体中,其中一些与溶酶体共定位。铁蛋白中铁的储存由于 FHsiRNA 而大大减少,导致转铁蛋白受体水平降低和从转铁蛋白中摄取的铁减少,从而导致铁的可用性增加。增加的铁可用性还增加了胱氨酸摄取和谷胱甘肽浓度,并减少了核内缺氧诱导因子 1-α的核易位和细胞条件培养基中血管内皮生长因子(VEGF)的积累。
结论:用特异性 siRNA 改变铁蛋白 H:L 比率的大多数影响归因于不稳定池中铁的可用性的变化。它们导致铁摄取和储存、铁蛋白合成和降解速率、VEGF 分泌和培养的晶状体上皮细胞中谷胱甘肽水平的显著变化。这些深远的影响清楚地表明,维持特定的 H:L 比率是基本细胞内稳态机制的一部分。
Invest Ophthalmol Vis Sci. 2005-10
Invest Ophthalmol Vis Sci. 2001-7
Invest Ophthalmol Vis Sci. 2009-1
Invest Ophthalmol Vis Sci. 2007-9
Int J Mol Sci. 2016-2-5
Oxid Med Cell Longev. 2013-12-3
Diabetes Technol Ther. 2014-4
Invest Ophthalmol Vis Sci. 2011-6-1
Invest Ophthalmol Vis Sci. 2009-4
Antioxid Redox Signal. 2008-6
Invest Ophthalmol Vis Sci. 2007-9
Invest Ophthalmol Vis Sci. 2005-10
Am J Physiol Cell Physiol. 2005-5